165 related articles for article (PubMed ID: 21747375)
1. Psoriasis: from bed to bench and back.
Garber K
Nat Biotechnol; 2011 Jul; 29(7):563-6. PubMed ID: 21747375
[No Abstract] [Full Text] [Related]
2. Suicidal thoughts end Amgen's blockbuster aspirations for psoriasis drug.
Schmidt C
Nat Biotechnol; 2015 Sep; 33(9):894-5. PubMed ID: 26348946
[No Abstract] [Full Text] [Related]
3. Guselkumab (Tremfya) for psoriasis.
Med Lett Drugs Ther; 2017 Nov; 59(1533):179-180. PubMed ID: 29125591
[No Abstract] [Full Text] [Related]
4. [Patient education. Information letter on treatment of psoriasis with infliximab (Remicade)].
Groupe de recherche sur psoriasis de Société française de dermatologie, mai 2011
Ann Dermatol Venereol; 2011 Dec; 138(12):865-7. PubMed ID: 22137633
[No Abstract] [Full Text] [Related]
5. New Injectable Drug Treats Moderate-To-Severe Plaque Psoriasis.
Aschenbrenner DS
Am J Nurs; 2017 Jun; 117(6):23. PubMed ID: 28541985
[No Abstract] [Full Text] [Related]
6. [Patient education. Information letter on treatment of psoriasis with ustekinumab (Stelara)].
Groupe de recherche sur psoriasis de Société française de dermatologie, mai 2011
Ann Dermatol Venereol; 2011 Dec; 138(12):874-5. PubMed ID: 22137636
[No Abstract] [Full Text] [Related]
7. [Ustekinumab].
Ortonne JP
Ann Dermatol Venereol; 2011 Dec; 138(12):848-50. PubMed ID: 22137626
[No Abstract] [Full Text] [Related]
8. Briakinumab versus Methotrexate for Psoriasis.
Wu JJ
N Engl J Med; 2012 Jan; 366(4):379-80; author reply 380. PubMed ID: 22276833
[No Abstract] [Full Text] [Related]
9. Briakinumab versus methotrexate for psoriasis.
Malgarini RB; Pimpinella G
N Engl J Med; 2012 Jan; 366(4):379; author reply 380. PubMed ID: 22276832
[No Abstract] [Full Text] [Related]
10. A promising step forward in psoriasis therapy.
Stern RS
JAMA; 2003 Dec; 290(23):3133-5. PubMed ID: 14679277
[No Abstract] [Full Text] [Related]
11. Advances in psoriasis treatment.
Schön MP
Lancet; 2005 Oct 15-21; 366(9494):1333-5. PubMed ID: 16226595
[No Abstract] [Full Text] [Related]
12. Long-term control of recalcitrant psoriasis with combination infliximab and methotrexate.
Warren RB; Brown BC; Carmichael AJ; Griffiths CE
Clin Exp Dermatol; 2009 Apr; 34(3):415-6. PubMed ID: 19120390
[No Abstract] [Full Text] [Related]
13. Broadalumab (Siliq)--another IL-17A antagonist for psoriasis.
Med Lett Drugs Ther; 2017 Jul; 59(1525):118-119. PubMed ID: 28699932
[No Abstract] [Full Text] [Related]
14. Infliximab for the treatment of severe pustular psoriasis.
Elewski BE
J Am Acad Dermatol; 2002 Nov; 47(5):796-7. PubMed ID: 12399781
[No Abstract] [Full Text] [Related]
15. Ustekinumab (Stelara) for psoriasis.
Med Lett Drugs Ther; 2010 Jan; 52(1330):7-8. PubMed ID: 20208473
[No Abstract] [Full Text] [Related]
16. [Infliximab].
Goujon C; Bachelez H
Ann Dermatol Venereol; 2011 Dec; 138(12):839-41. PubMed ID: 22137623
[No Abstract] [Full Text] [Related]
17. Brodalumab versus ustekinumab in psoriasis.
Fioranelli M; Roccia MG; Lotti T
Dermatol Ther; 2016 Sep; 29(5):298. PubMed ID: 26627075
[No Abstract] [Full Text] [Related]
18. Clinical experience of secukinumab in the treatment of erythrodermic psoriasis: a case series.
Weng HJ; Wang TS; Tsai TF
Br J Dermatol; 2018 Jun; 178(6):1439-1440. PubMed ID: 29265175
[No Abstract] [Full Text] [Related]
19. Clinical experience with infliximab biosimilar in psoriasis.
Ricceri F; Pescitelli L; Lazzeri L; Prignano F
Br J Dermatol; 2017 Dec; 177(6):e347-e348. PubMed ID: 28646577
[No Abstract] [Full Text] [Related]
20. Infliximab- and methotrexate-resistant rebound of psoriasis after discontinuation of efalizumab (Raptiva).
Thielen AM; Barde C; Saurat JH
Br J Dermatol; 2006 Oct; 155(4):846-7. PubMed ID: 16965444
[No Abstract] [Full Text] [Related]
[Next] [New Search]
